Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Hematology
Volume 2018, Article ID 9840405, 5 pages
https://doi.org/10.1155/2018/9840405
Case Report

A Rare Case of Systemic AL Amyloidosis with Muscle Involvement: A Misleading Diagnosis

1UO di Ematologia e CTMO, Azienda Ospedaliero-Universitaria di Parma and Department of Medicine and Surgery, University of Parma, Parma, Italy
2Department of Biomedical and Neuromotor Sciences, Alma Mater University of Bologna, Bologna, Italy
3Muscle and Nerve Histopathology Laboratory, Neurology Unit, Azienda Ospedaliero-Universitaria di Parma, University of Parma, Parma, Italy
4Department of Diagnostic Medicine, Electron Microscopy Laboratory, IRCCS Fondazione Policlinico San Matteo and University of Pavia, Pavia, Italy
5Pathology Unit, Azienda Ospedaliero-Universitaria di Parma, Parma, Italy

Correspondence should be addressed to Nicola Giuliani; ti.rpinu@inailuig.alocin

Received 24 July 2017; Accepted 27 December 2017; Published 31 January 2018

Academic Editor: Uma Dasgupta

Copyright © 2018 Fabrizio Accardi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. G. Merlini, A. D. Wechalekar, and G. Palladini, “Systemic light chain amyloidosis: an update for treating physicians,” Blood, vol. 121, no. 26, pp. 5124–5130, 2013. View at Publisher · View at Google Scholar · View at Scopus
  2. E. Muchtar, D. Derudas, M. Mauermann et al., “Systemic immunoglobulin light chain amyloidosis–associated myopathy: presentation, diagnostic pitfalls, and outcome,” Mayo Clinic Proceedings, vol. 91, no. 10, pp. 1354–1361, 2016. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Liewluck and M. Milone, “Characterization of isolated amyloid myopathy,” European Journal of Neurology, vol. 24, no. 12, pp. 1437–1445, 2017. View at Publisher · View at Google Scholar
  4. I. Lousada, R. L. Comenzo, H. Landau, S. Guthrie, and G. Merlini, “Light chain amyloidosis: patient experience survey from the Amyloidosis Research Consortium,” Advances in Therapy, vol. 32, no. 10, pp. 920–928, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Merlini and V. Bellotti, “Molecular mechanisms of amyloidosis,” New England Journal of Medicine, vol. 349, no. 6, pp. 583–596, 2003. View at Publisher · View at Google Scholar · View at Scopus
  6. M. A. Gertz, R. Comenzo, R. H. Falk et al., “Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis,” American Journal of Hematology, vol. 79, no. 4, pp. 319–328, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. J. E. Chapin, M. Kornfeld, and A. Harris, “Amyloid myopathy: characteristic features of a still underdiagnosed disease,” Muscle & Nerve, vol. 31, no. 2, pp. 266–272, 2005. View at Publisher · View at Google Scholar · View at Scopus
  8. L. W. Ostrow, A. M. Corse, B. M. Morrison et al., “Expanding the spectrum of monoclonal light chain deposition disease in muscle,” Muscle & Nerve, vol. 45, no. 5, pp. 755–761, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. A. Dispenzieri, M. A. Gertz, R. A. Kyle et al., “Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis,” Journal of Clinical Oncology, vol. 22, no. 18, pp. 3751–3757, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. A. D. Wechalekar, S. O. Schonland, E. Kastritis et al., “A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis,” Blood, vol. 121, no. 17, pp. 3420–3427, 2013. View at Publisher · View at Google Scholar · View at Scopus
  11. M. A. Gertz and R. A. Kyle, “Myopathy in primary systemic amyloidosis,” Journal of Neurology, Neurosurgery & Psychiatry, vol. 60, no. 6, pp. 655–660, 1996. View at Publisher · View at Google Scholar
  12. R. J. Walters, “Muscle diseases: mimics and chameleons,” Practical Neurology, vol. 14, no. 5, pp. 288–298, 2014. View at Publisher · View at Google Scholar · View at Scopus
  13. S. Spuler, A. Emslie-Smith, and A. G. Engel, “Amyloid myopathy: an underdiagnosed entity,” Annals of Neurology, vol. 43, no. 6, pp. 719–728, 1998. View at Publisher · View at Google Scholar · View at Scopus
  14. C. Delaporte, B. Varet, M. Fardeau, D. Nochy, and A. Ract, “In vitro myotrophic effect of serum kappa chain immunoglobulins from a patient with kappa light chain myeloma and muscular hypertrophy,” Journal of Clinical Investigation, vol. 78, no. 4, pp. 922–927, 1986. View at Publisher · View at Google Scholar
  15. S. Enqvist, K. Sletten, F. J. Stevens, U. Hellman, and P. Westermark, “Germ line origin and somatic mutations determine the target tissues in systemic AL-amyloidosis,” PLoS One, vol. 2, no. 10, Article ID e981, 2007. View at Publisher · View at Google Scholar · View at Scopus